PILOT STUDY ON THE EFFECTIVENESS OF CHOLINE ALFOSCERATE IN THE UNDER THRESHOLD DEPRESSION OF THE ELDERLY
EU CTIS ID: 2025-520899-25-00
What this study is testing
The primary objective of the study is to evaluate the efficacy of choline alfoscerate on subthreshold depression in elderly patients.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 1. Age = 65 years 2. From 2 to 4 depressive symptoms present for at least two weeks prior to enrollment (Judd et al., 1994) 3. Mini-Mental State Examination (MMSE) score = 24 4. Montreal Cognitive Assessment (MOCA) score < 26 5. Patients able to understand and sign informed consent 6. Informed consent signature
You likely can't join if
- 1. Any contraindication to treatment or intolerance to choline alfoscerate 2. Diagnosis of Major Depressive Episode or Dysthymia 3. Diagnosis of Schizophrenia or other psychotic disorders, Bipolar Disorder or Dementia 4. Alcohol / drug / substance abuse or dependence 5. Severe organic disease (eg major surgery, metastatic cancer, stroke, severe neurological disorder, myocardial infarction, chronic heart failure) 6. Treatment with antidepressants or psychotherapy within 2 weeks prior to recruitment 7. Any condition which, in the opinion of the investigator, might put the patient at risk by participation in this study 8. Patients involved in other clinical trials
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.